Five realistic ways to turn granted patents into revenue in 2026, what each one costs, and why a monetization assessment comes before any of them.
A granted patent is not revenue. It is an option on revenue, and in 2026 there are five realistic ways to exercise it: license it, sell it, enforce it, borrow against it, or put it to work inside a commercial deal. Which one fits depends mostly on whether someone is already practicing your claims, and a monetization assessment answers that for around $5,000, before you spend anything on lawyers, brokers, or bankers.
Licensees, buyers, litigation funders, and lenders pay for position over products that are already in the market. Ideas do not move the price, and neither does what the patent cost you to get. That last part is the one CFOs find hardest, because the prosecution invoices were real.
Louis Carbonneau, who brokers patents at Tangible IP, wrote in December 2025 that buyers pay for assertion value and that 98 to 99 percent of the portfolios his firm reviews have no meaningful market value. That matches what we see, and it is the reason to spend a little to learn which side of that line you are on before spending a lot.
The tool for that is evidence of use: a documented mapping of a real product’s features against your claim language, element by element. Our approach is to run an inexpensive, non-legal version first and to commission legal-grade claim charts only when the result will be shown to a board, a funder, a lender, or the other side of a table.
The triage version is the core of a monetization assessment, which starts around $5,000 and covers what you own, who appears to practice it, which path is realistic, and a rough range for what it could fetch. We keep it separate from a valuation on purpose. An investor-grade valuation runs around $25,000, and you buy that once a path is chosen and a counterparty is real.
A license is permission. You let another company make, use, or sell what you claim, on agreed terms, and you keep ownership the whole time. Our royalty-rate guide puts patent royalties between 0.1 and 8 percent of net sales across published surveys, with roughly 3 to 6 percent typical, higher in software and pharma and down near 1 to 2 percent in semiconductors. The old 25 percent rule was rejected by the Federal Circuit as damages evidence in 2011; do not let anyone anchor on it.
IIPRD argued in June 2026 that licensing has overtaken litigation as the preferred way to monetize, and as a description of what owners would rather do, it is right. Our pushback is that licensing only works with enforcement behind it. A license from a company already practicing your claims is a negotiated settlement of a dispute it believes you could win. In the programs we have supported, a licensing letter to a large implementer with no claim chart behind it and no visible path to court gets one reply: silence. Licensing and enforcement are one path at two speeds.
So a realistic licensing program needs evidence of use on named products, enough remaining life to be worth the licensee’s legal review (terms generally run 20 years from filing, and in our experience a family with four years left is a hard sell), a precisely defined royalty base, and a budget for outreach, because the first six months tend to be mostly follow-up. Get your patent attorney in before terms are discussed; scope, field of use, sublicensing, and audit rights are where a decent royalty rate gets quietly hollowed out.
Lumenci’s June 2026 guide has the standard framing: license for recurring revenue and ownership, sell for capital now or a simpler portfolio, and do not treat every patent the same. We would sharpen that last point: segment by evidence of use and remaining life, not by which inventions the engineering team is proudest of.
In the engagements we support, a sale wins in four situations. The patent covers a market you have left or never entered. You cannot fund or stomach enforcement and the buyer can. You need cash on a schedule. Or the family is running short on life, since patents with under three years left rarely sell at any price.
Buyers check the same things in every channel: active use of the technology, claims broad enough to matter but clean enough to survive challenge, years of life left, a family, a clean prosecution history, and title with no gaps. Most negotiated sales close in the five to six figures, with outliers far higher, over six months to two years. By Carbonneau’s read of the 2024 data, about 21 percent of brokered packages sold: a thin market that pays well for the few that clear the bar.
Brokered or direct? Brokers commonly charge 15 to 35 percent of the price. We tell clients to go direct when they already know who is practicing the claims, and to use a broker when the buyer is unknown and the package is large enough to carry the commission. We take no success fees and broker nothing.
Before you call a broker or a litigator, get a rough size on the market your patents touch. The Patent Valuation Calculator takes five inputs and returns a broad monetization-market range; it is a screening step, not a valuation, but it tells you in a few minutes whether the licensing conversation deserves a CFO’s afternoon.
The 2026 picture is more suits, fewer challenges, and concentrated payouts. Lex Machina’s August 2026 report counted 4,547 patent cases filed in 2025, up 19.6 percent and a ten-year high, while inter partes review petitions fell about 8 percent to 1,208 and the first half of 2026 brought only 201 PTAB petitions. The same report counted $2.353 billion in damages in 2025 across just 63 cases. Filings have cooled since: Unified Patents counted 1,921 district court cases in the first half of 2026, down 18.4 percent year over year. Our read: friendlier to patent owners than a few years ago, and still lottery-shaped.
Costs first. AIPLA’s economic survey, as cited in a November 2025 public comment to the USPTO, put the median cost of a patent case through appeal, on the defendant’s side, at roughly $600,000 when under $1 million is at stake and $3.625 million when more than $25 million is; our litigation cost page puts the middle figure around $2.8 million. One 2026 practice guide puts the national median time to trial near 29 months.
Many owners who enforce do not write those checks themselves; the GAO heard from large technology companies that more than half of the patent suits against them had confirmed or suspected outside funding. Westfleet’s 2025 market report, summarized by Risk & Insurance, found new litigation-finance commitments up about 23 percent in 2025 after two down years, with patent cases taking 27 percent of the money. The terms are steep: the GAO found some funders require two to three times their investment back before the patent owner sees a dollar, and contingent counsel and funders together commonly take 20 to 40 percent of recoveries while accepting a small share of what they are shown.
Our view is that enforcement is a path for a specific patent and a specific owner. The patent needs a core feature, clean evidence of use, a solvent defendant, and years of life left. The owner needs to be able to wait two or three years and, if it also sells products, to absorb a counter-suit. Whether to file is a call for a patent litigator; our job beforehand is to check whether you have what funders screen for, so that conversation starts from a claim chart and a damages number.
A patent nobody practices is a certificate. A patent somebody practices is a negotiation.
WIPO, which defines IP-backed finance as pledging IP rights or their cash flows to secure a loan, calls the market growing but still largely nascent. In the U.S. the lenders are specialist IP funds, venture debt providers, and insurance-backed programs; commercial banks seldom take patents as primary collateral in the deals we see.
They value patents as if they had to sell them, so the checklist is a buyer’s: clean recorded title, maintenance fees current, no prior exclusive license, and demonstrable transfer value through royalties, evidence of use, or an active market. The programs we have seen advance only a fraction of the appraised figure, and a lending-grade valuation typically starts at $50,000. In our experience an existing royalty stream is the strongest collateral you can offer, and patents that are infringed but not yet licensed can also support lending, with the lender taking recourse to the litigation proceeds.
Keep the assets alive meanwhile. U.S. maintenance fees fall due at 3.5, 7.5, and 11.5 years after issue, currently $2,150, $4,040, and $8,280 at the standard rate, and a patent that lapses stops being enforceable unless it is revived, which a lender’s counsel will notice before you do.
The paths brokers never pitch are the ones we see pay soonest. A patent in the sales team’s briefcase changes a customer conversation: your product is the one a competitor cannot copy without a license, which protects margin. In a supply, distribution, or joint-venture negotiation, a portfolio is a contribution you can bring instead of cash, and when a company approaches to buy a patent, the counter is often a partnership or supply deal instead, which we have found tends to be the better outcome.
We went through the full menu on Invent Anything episode 10: 6 Ways of Making Money with Patents, including the quieter ones: gross margin, brand, contract terms, and stock price.
A small share of assets, around 10 to 20 percent in our portfolio valuation guide, carries most of a portfolio’s value, and a portfolio is valued on the products and markets it touches rather than patent by patent. So package around a product or market: the anchor patent, its continuations and foreign family, the evidence-of-use charts, a written list of future applications (the buyers we have dealt with pay for room to grow). Check the assignment chain before a buyer’s counsel does; recording an assignment with the USPTO costs nothing when filed electronically, which makes a gap hard to explain.
The order matters more than any single step. Assessment first, at around $5,000, to learn what you have and who is practicing it. Then choose the path. Then buy the grade of valuation that path needs: investor-grade at around $25,000 for a board or a raise, lending or transaction grade from $50,000. We have watched owners reverse that order and end up with an expensive number and no plan for it.
Is anyone using it? If you cannot name a product that reads on your claims, the realistic paths are commercial use and a modest sale. Is the title clean and are the fees paid? A gap in the assignment chain or a lapsed maintenance fee stops every path on the menu. How many years are left? Licensing and enforcement want years of life, ideally a decade, a sale wants more than three, and a lender wants both.
Talk with our team about a monetization assessment if you have granted patents that are not paying their way; we will tell you which of the five paths is worth your time, and which are not.
Work with ipCapital Group
From invention to monetization, our team has guided 2,000+ engagements across the full IP lifecycle. Start with a free 30-minute discovery call.
Written by
Seth Cronin